Patents by Inventor Charles L. Sawyers

Charles L. Sawyers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571
    Patent number: 8697348
    Abstract: The invention described herein relates to novel genes and their encoded proteins, termed Mutants Associated with Resistance to STI-571 (e.g., T315I Bcr-Abl), and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express MARS. The invention further provides methods for identifying molecules that bind to and/or modulate the functional activity of MARS.
    Type: Grant
    Filed: July 12, 2006
    Date of Patent: April 15, 2014
    Assignee: The Regent of the University of California
    Inventors: Charles L. Sawyers, Mercedes E. Gorre, Neil Pravin Shah, John Nicoll
  • Treatment of hyperproliferative disorders with diarylhydantoin compounds
    Patent number: 8658681
    Abstract: The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
    Type: Grant
    Filed: April 17, 2012
    Date of Patent: February 25, 2014
    Assignee: The Regents of the University of California
    Inventors: Charles L. Sawyers, Michael E. Jung, Charlie D. Chen, Samedy Ouk, Chris Tran, John Wongvipat
  • Diarylthiohydantoin compounds
    Patent number: 8648105
    Abstract: The present invention relates to diarylthiohydantoin compounds and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: February 11, 2014
    Assignee: The Regents of the University of California
    Inventors: Michael E. Jung, Dongwon Yoo, Charles L. Sawyers, Chris Tran, John Wongvipat
  • Mutations in the Bcr-Abl tyrosine kinase associated with resistance to ST1-571
    Patent number: 8586291
    Abstract: The invention described herein relates to novel genes and their encoded proteins, termed Mutants Associated with Resistance to STI-571 (e.g., T315I Bcr-Abl), and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express MARS. The invention further provides methods for identifying molecules that bind to and/or modulate the functional activity of MARS.
    Type: Grant
    Filed: March 11, 2009
    Date of Patent: November 19, 2013
    Assignee: The Regents of the University of California
    Inventors: Charles L. Sawyers, Mercedes E. Gorre, Neil Pravin Shah, John Nicoll
  • Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
    Patent number: 8445507
    Abstract: A hydantoin compound useful for the prevention or treatment of hyperproliferative diseases or disorders.
    Type: Grant
    Filed: March 27, 2007
    Date of Patent: May 21, 2013
    Assignee: The Regents of the University of California
    Inventors: Michael E. Jung, Charles L. Sawyers, Samedy Ouk, Chris Tran, John Wongvipat
  • ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES
    Publication number: 20130072511
    Abstract: Described herein, inter alia, are compounds useful for the prevention or treatment of hyperproliferative diseases or disorders.
    Type: Application
    Filed: September 13, 2012
    Publication date: March 21, 2013
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Michael E. Jung, Charles L. Sawyers, Samedy Ouk, Chris Tran, John Wongvipat
  • DIARYLHYDANTOIN COMPOUNDS
    Publication number: 20130034501
    Abstract: The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone lefiactory prostate cancer.
    Type: Application
    Filed: September 14, 2012
    Publication date: February 7, 2013
    Applicant: The Regents of the University of California
    Inventors: Charles L. Sawyers, Michael E. Jung, Charlie D. Chen, Samedy Ouk, Derek Welsbie, Chris Tran, John Wongvipat, Dongwon Yoo
  • TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS
    Publication number: 20120295944
    Abstract: The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
    Type: Application
    Filed: April 17, 2012
    Publication date: November 22, 2012
    Applicant: The Regents of the University of California
    Inventors: Charles L. Sawyers, Michael E. Jung, Charlie D. Chen, Samedy Ouk, Derek Welsbie, Chris Tran, John Wongvipat, Dongwon Yoo
  • MUTATIONS IN THE BCR-ABL TYROSINE KINASE ASSOCIATED WITH RESISTANCE TO STI-571
    Publication number: 20120282622
    Abstract: The invention described herein relates to novel genes and their encoded proteins, termed Mutants Associated with Resistance to STI-571 (e.g., T315I Bcr-Abl), and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express MARS. The invention further provides methods for identifying molecules that bind to and/or modulate the functional activity of MARS.
    Type: Application
    Filed: July 12, 2012
    Publication date: November 8, 2012
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Charles L. Sawyers, Mercedes E. Gorre, Neil Pravin Shah, John Nicoll
  • DIARYLTHIOHYDANTOIN COMPOUNDS
    Publication number: 20120190718
    Abstract: The present invention relates to diarylthiohydantoin compounds and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
    Type: Application
    Filed: December 21, 2011
    Publication date: July 26, 2012
    Applicant: The Regents of the University of California
    Inventors: Michael E. Jung, Dongwon Yoo, Charles L. Sawyers, Chris Tran, John Wongvipat
  • Treatment of hyperproliferative disorders with diarylhydantoin compounds
    Patent number: 8183274
    Abstract: The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
    Type: Grant
    Filed: February 18, 2010
    Date of Patent: May 22, 2012
    Assignee: The Regents of the University of California
    Inventors: Charles L. Sawyers, Michael E. Jung, Charlie D. Chen, Samedy Ouk, Chris Tran, John Wongvipat
  • Diarylthiohydantoin compounds
    Patent number: 8110594
    Abstract: The present invention relates to diarylthiohydantoin compounds and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: February 7, 2012
    Assignee: The Regents of the University of California
    Inventors: Michael E. Jung, Dongwon Yoo, Charles L. Sawyers, Chris Tran, John Wongvipat
  • MUTATIONS IN THE BCR-ABL TYROSINE KINASE ASSOCIATED WITH RESISTANCE TO STI-571
    Publication number: 20120021425
    Abstract: The invention described herein relates to novel genes and their encoded proteins, termed Mutants Associated with Resistance to STI-571 (e.g., T315I Bcr-Abl), and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express MARS. The invention further provides methods for identifying molecules that bind to and/or modulate the functional activity of MARS.
    Type: Application
    Filed: September 29, 2011
    Publication date: January 26, 2012
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Charles L. Sawyers, Mercedes E. Gorre, Neil Pravin Shah, John Nicoll
  • Methods and materials for assessing prostate cancer therapies
    Patent number: 8034548
    Abstract: Using microarray-based profiling of isogenic prostate cancer xenograft models, we found that a modest (2-5 fold) increase in androgen receptor (AR) mRNA was the only expression change consistently associated with developing resistance to antiandrogen therapy. Increased levels of AR confer resistance to anti-androgens by amplifying signal output from low levels of residual ligand and altering the normal response to antagonists. This invention provides cell based assays for use in the examination of new therapeutic modalities and provides insight toward the design of novel antiandrogens.
    Type: Grant
    Filed: December 16, 2004
    Date of Patent: October 11, 2011
    Assignee: The Regents of the University of California
    Inventors: Charles L. Sawyers, Charlie D. Chen, Derek S. Welsbie
  • Molecular determinants of EGFR kinase inhibitor response in glioblastoma
    Publication number: 20110045459
    Abstract: The invention disclosed herein provides methods for the examination and/or quantification of biochemical pathways that are disregulated in pathologies such as cancer and to reagents and kits adapted for performing such methods.
    Type: Application
    Filed: April 21, 2006
    Publication date: February 24, 2011
    Inventors: Paul S. Mischel, Ingo K. Mellinghoff, Yinglin Wang, Timothy F. Cloughesy, Charles L. Sawyers
  • ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES
    Publication number: 20110003839
    Abstract: A hydantoin compound useful for the prevention or treatment of hyperproliferative diseases or disorders.
    Type: Application
    Filed: March 27, 2007
    Publication date: January 6, 2011
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Michael E. Jung, Charles L. Sawyers, Samedy Ouk, Chris Tran, John Wongvipat
  • MUTATIONS IN THE BCR-ABL TYROSINE KINASE ASSOCIATED WITH RESISTANCE TO STI-571
    Publication number: 20100248241
    Abstract: The invention described herein relates to novel genes and their encoded proteins, termed Mutants Associated with Resistance to STI-571 (e.g., T315I Bcr-Abl), and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express MARS. The invention further provides methods for identifying molecules that bind to and/or modulate the functional activity of MARS.
    Type: Application
    Filed: March 24, 2010
    Publication date: September 30, 2010
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Charles L. Sawyers, Mercedes E. Gorre, Neil Pravin Shah, John Nicoll
  • DIARYLHYDANTOIN COMPOUNDS
    Publication number: 20100210665
    Abstract: The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
    Type: Application
    Filed: February 18, 2010
    Publication date: August 19, 2010
    Applicant: The Regents of the University of California
    Inventors: Charles L. Sawyers, Michael E. Jung, Charlie D. Chen, Samedy Ouk, Derek Welsbie, Chris Tran, John Wongvipat
  • TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS
    Publication number: 20100172975
    Abstract: The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
    Type: Application
    Filed: February 18, 2010
    Publication date: July 8, 2010
    Applicant: The Regents of the University of California
    Inventors: Charles L. Sawyers, Michael E. Jung, Charlie D. Chen, Samedy Ouk, Derek Welsbie, Chris Tran, John Wongvipat, Dongwon Yoo
  • Methods and materials for assessing prostate cancer therapies and compounds
    Patent number: 7718684
    Abstract: A modest (2-5 fold) increase in androgen receptor (AR) mRNA is the only expression change consistently associated with developing resistance to antiandrogen therapy. Increased levels of AR confer resistance to anti-androgens by amplifying signal output from low levels of residual ligand and altering the normal response to antagonists. This invention provides cell based assays for use in the examination of new therapeutic modalities and provides for the design of novel antiandrogen compounds.
    Type: Grant
    Filed: February 23, 2005
    Date of Patent: May 18, 2010
    Assignee: The Regents of the University of California
    Inventors: Michael E. Jung, Samedy Ouk, Charles L. Sawyers, Charlie D. Chen, Derek Welsbie